Cite
HARVARD Citation
Besse, B. et al. (n.d.). 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). European journal of cancer. pp. S717-S718. [Online].